IL134345A0 - Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon - Google Patents

Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon

Info

Publication number
IL134345A0
IL134345A0 IL13434598A IL13434598A IL134345A0 IL 134345 A0 IL134345 A0 IL 134345A0 IL 13434598 A IL13434598 A IL 13434598A IL 13434598 A IL13434598 A IL 13434598A IL 134345 A0 IL134345 A0 IL 134345A0
Authority
IL
Israel
Prior art keywords
multiple sclerosis
methods
treatment
consensus interferon
patients afflicted
Prior art date
Application number
IL13434598A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL134345A0 publication Critical patent/IL134345A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13434598A 1997-08-15 1998-07-15 Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon IL134345A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/911,893 US6013253A (en) 1997-08-15 1997-08-15 Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
PCT/US1998/014622 WO1999008702A1 (en) 1997-08-15 1998-07-15 Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon

Publications (1)

Publication Number Publication Date
IL134345A0 true IL134345A0 (en) 2001-04-30

Family

ID=25431058

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13434598A IL134345A0 (en) 1997-08-15 1998-07-15 Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
IL134345A IL134345A (en) 1997-08-15 2000-02-02 Use of Interferon Consensus in drug preparation, combination and pharmaceutical preparation that includes Interferon Consensus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL134345A IL134345A (en) 1997-08-15 2000-02-02 Use of Interferon Consensus in drug preparation, combination and pharmaceutical preparation that includes Interferon Consensus

Country Status (17)

Country Link
US (1) US6013253A (de)
EP (1) EP1003546B1 (de)
JP (1) JP3813440B2 (de)
KR (1) KR100415636B1 (de)
CN (1) CN1183963C (de)
AT (1) ATE338563T1 (de)
AU (1) AU741074B2 (de)
CA (1) CA2299361C (de)
CY (1) CY1107314T1 (de)
DE (1) DE69835823T2 (de)
DK (1) DK1003546T3 (de)
ES (1) ES2267188T3 (de)
HU (1) HU229045B1 (de)
IL (2) IL134345A0 (de)
PT (1) PT1003546E (de)
TW (1) TW474817B (de)
WO (1) WO1999008702A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
EP3064215A1 (de) * 2002-10-16 2016-09-07 Samuel F. Hunter Verfahren zur behandlung von demyelinisierender erkrankung des zentralen nervensystems
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
AU2005244448B2 (en) * 2004-05-17 2011-03-17 Ares Trading S.A. Hydrogel interferon formulations
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
ES2381674T3 (es) 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
US20100028296A1 (en) * 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
AU2005335900B2 (en) 2005-08-26 2012-03-29 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
US8178083B2 (en) * 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
US9925151B2 (en) 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
PL2234645T3 (pl) * 2007-12-20 2012-10-31 Merck Serono Sa Preparaty interferonu-beta modyfikowanego PEG
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
HUE046944T2 (hu) 2013-07-18 2020-03-30 Xalud Therapeutics Inc Készítmény gyulladásos ízületi betegség kezelésére
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон
TW202537627A (zh) 2017-11-24 2025-10-01 德商馬克專利公司 用於治療進展型多發性硬化症之克拉屈濱(cladribine)療程
US20240226284A1 (en) 2020-09-10 2024-07-11 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
BR9007883A (pt) * 1989-11-29 1992-09-29 Synergen Inc Producao de inibidor de interleucina-1 humana recombinante
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
CA2118119C (en) * 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
RU2126262C1 (ru) * 1992-09-17 1999-02-20 Амген Боулдер Инк. Фармацевтическая композиция
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH08511507A (ja) * 1993-03-08 1996-12-03 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 哺乳動物宿主の結合組織を処置するための遺伝子導入
US5932208A (en) * 1993-03-19 1999-08-03 Vacsyn S.A. Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
FR2706772A1 (en) * 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
ATE203415T1 (de) * 1994-02-08 2001-08-15 Amgen Inc Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Also Published As

Publication number Publication date
AU741074B2 (en) 2001-11-22
DE69835823D1 (de) 2006-10-19
HU229045B1 (en) 2013-07-29
HK1030157A1 (en) 2001-04-27
DK1003546T3 (da) 2006-10-30
CY1107314T1 (el) 2012-11-21
EP1003546A1 (de) 2000-05-31
EP1003546B1 (de) 2006-09-06
HUP0002755A2 (hu) 2000-12-28
JP3813440B2 (ja) 2006-08-23
CA2299361A1 (en) 1999-02-25
JP2001515047A (ja) 2001-09-18
ES2267188T3 (es) 2007-03-01
HUP0002755A3 (en) 2001-11-28
IL134345A (en) 2011-03-31
CN1267225A (zh) 2000-09-20
KR20010030563A (ko) 2001-04-16
US6013253A (en) 2000-01-11
ATE338563T1 (de) 2006-09-15
TW474817B (en) 2002-02-01
KR100415636B1 (ko) 2004-01-24
DE69835823T2 (de) 2007-08-09
WO1999008702A1 (en) 1999-02-25
CA2299361C (en) 2009-09-29
PT1003546E (pt) 2006-12-29
AU8300698A (en) 1999-03-08
CN1183963C (zh) 2005-01-12

Similar Documents

Publication Publication Date Title
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
TW265265B (de)
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
IL108114A0 (en) Therapeutic potentiated interferon combination
IL138665A0 (en) Peptide factor
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
IL130785A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
NZ299257A (en) Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
NZ514629A (en) PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
GB9903091D0 (en) Therapeutic nucleoside compound
GEP19991514B (en) Method for Treatment with Interferon
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon
EP1908477A3 (de) Kombination aus Temozolomid und pegyliertem Interferon-alpha zur Krebsbehandlung

Legal Events

Date Code Title Description
FF Patent granted